Healthcare research company Tevogen Bio reported on Monday the receipt of the necessary funding to support all clinical trials of its investigational, potentially curative COVID-19 treatment from HMP Partners of New Jersey, a medical investment firm.
The company said its Investigational New Drug (IND) application for its proprietary antigen-specific T cell therapy is under review by the US Food and Drug Administration (FDA).
According to the company, a patient's own T cells reportedly activates and responds to the infection, which is the mechanism that the body employs to rid itself of SARS-CoV-2. Its proprietary solution enables a single donation from a donor to generate more than a thousand doses of COVID-19 specific cytotoxic T cells.
Yale's Dr Ryan Saadi is leading the efforts and is among those who are financing the trials.
Under the guidance of the lead investigator Dr Neal Flomenberg, chair of the Department of Medical Oncology at Thomas Jefferson University, Tevogen will study its investigational treatment, TVGN-489, allogeneic T cells that have been programmed and grown in the laboratory, for its safety and capability to recognize and destroy COVID-19 infected cells in its upcoming trials.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial